WebDoctor Encyclopedia

Endocrine

Adrenocortical Carcinoma

A rare, aggressive cancer of the adrenal cortex that often overproduces hormones such as cortisol, and is treated mainly with complete surgery and mitotane.

Medically reviewed Last reviewed October 16, 2026

Adrenocortical Carcinoma: A Comprehensive Guide for Patients and Caregivers

Introduction Adrenocortical carcinoma (ACC) is a rare but highly aggressive malignancy originating from the cells of the adrenal cortex, the outer layer of the adrenal glands responsible for producing essential hormones like cortisol, aldosterone, and androgens. Situated atop each kidney, these small, triangular glands play a vital role in regulating metabolism, stress response, blood pressure, and electrolyte balance.

ACC accounts for less than 0.2% of all cancer diagnoses globally, with an estimated annual incidence of 1-2 cases per million individuals. Despite its rarity, ACC poses significant clinical challenges due to its propensity for rapid growth, early metastasis, and frequent presentation at an advanced stage.

Epidemiology and Risk Factors

Understanding who is affected and potential contributing factors helps contextualize the disease.

Factor Key facts
Incidence Rare worldwide; higher rates in southern Brazil, linked to an inherited TP53 founder variant.
Age and sex Peaks at 40–60 years, with a smaller peak in childhood; slightly more common in women (about 1.5:1).
Sporadic cases About 75–80% arise from acquired (somatic) mutations, with no family history.
Environment No proven environmental cause; links to hormonal exposures are weak.
Inherited syndrome Gene(s) Link with ACC
Li-Fraumeni syndrome TP53 Core tumour of the syndrome, especially in children.
Beckwith-Wiedemann syndrome 11p15 imprinting (IGF2, H19) Raised risk of embryonal tumours, including ACC and Wilms tumour.
Familial adenomatous polyposis APC Small increase in ACC risk.
MEN1 MEN1 Mainly pituitary, parathyroid and pancreatic tumours; ACC risk also raised.
Lynch syndrome MLH1, MSH2 and others Moderately increased ACC risk.

It is crucial to emphasize that having a risk factor does not mean ACC will develop, and many ACC patients have no identifiable risk factors. Conversely, not having known risk factors does not rule out the diagnosis.

Pathophysiology: How ACC Develops

ACC arises from the malignant transformation of a single cell within the adrenal cortex’s three zones (zona glomerulosa, fasciculata, reticularis). This transformation involves a complex interplay of genetic and epigenetic alterations leading to uncontrolled cell proliferation, evasion of cell death, invasive growth, and metastatic potential.

Alteration What it does
TP53 mutation Loss of a key tumour suppressor; common in children and Li-Fraumeni cases.
CTNNB1 mutation Switches on the Wnt/beta-catenin growth pathway.
IGF2 overexpression Loss of imprinting at 11p15 drives growth through IGF2.
TERT promoter mutation Activates telomerase, letting cells divide indefinitely.
Chromosomal instability Widespread gains and losses (e.g. 1p, 17p loss; 5q, 12q gain).
Type Share How it presents
Functional ACC About 40–60% Hormone excess syndromes (cortisol, aldosterone, androgens, oestrogens).
Non-functional ACC About 40–60% Effects of the mass itself: pain, fullness, spread.

Understanding these pathways is vital for developing targeted therapies, though current treatment remains largely centered on surgery and mitotane, with molecular insights guiding future research.

How Does It Look? (Gross and Microscopic Appearance)

Understanding the tumor’s physical and histological characteristics is fundamental to diagnosis, often confirmed only after surgical removal (adrenalectomy). The appearance provides critical clues distinguishing ACC from the much more common benign adrenal adenoma.

Gross (Macroscopic) Appearance

When viewed with the naked eye (during surgery or autopsy), ACC typically presents with features reflecting its aggressive nature:

  • Size: ACC tumors are often large at diagnosis due to asymptomatic growth in the retroperitoneum. The median size is frequently >5-6 cm, and tumors exceeding 10 cm (giant ACC) are not uncommon. Size correlates with malignancy risk and stage.
  • Shape and Borders: Tumors are usually irregular, infiltrative, and poorly circumscribed, invading surrounding tissues (kidney, liver, vasculature, retroperitoneal fat, diaphragm). This contrasts sharply with the smooth, well-defined, encapsulated borders of benign adenomas.
  • Color and Texture: The cut surface often appears yellowish, tan, or brownish, reflecting high lipid content (similar to normal cortex). However, areas of hemorrhage (reddish-brown), necrosis (yellowish-white, fibrous, or cystic degeneration due to outgrowing blood supply), and cystic change are frequently present, especially in larger tumors. Hemorrhage and necrosis are more suggestive of malignancy than the usually homogeneous yellow appearance of adenomas.
  • Presence of Invasion: Direct visualization of invasion into adjacent organs (e.g., kidney parenchyma, inferior vena cava, liver) or lymph nodes is a definitive macroscopic sign of malignancy.

Table 1: Gross Features Differentiating ACC from Adenoma

Feature Adrenocortical Carcinoma (ACC) Benign Adrenal Adenoma
Typical Size Often >5-6 cm at diagnosis; frequently >10 cm Usually <4 cm; rarely >6 cm
Borders Irregular, infiltrative, poorly circumscribed Smooth, well-defined, often encapsulated
Cut Surface Yellow/tan; frequent hemorrhage, necrosis, cysts Homogeneous yellow; rare hemorrhage/necrosis
Invasion Common into kidney, liver, vein, fat, diaphragm Absent
Consistency Variable; may be friable due to necrosis Usually firm and solid

Microscopic (Histopathological) Appearance

The definitive diagnosis of ACC relies on microscopic examination of tumor tissue by a pathologist. Specific criteria, most notably the Weiss scoring system, are used to distinguish ACC from adenoma based on features reflecting malignancy.

Weiss score: each feature scores 1 point. A total of 3 or more points suggests carcinoma; 0–2 suggests adenoma.

Weiss feature Points to carcinoma when
Nuclear grade High grade: marked atypia, coarse chromatin, prominent nucleoli.
Mitotic rate More than 5 mitoses per 50 high-power fields.
Atypical mitoses Abnormal (e.g. multipolar) dividing cells are present.
Clear cells Clear cells make up 25% or less of the tumour.
Architecture Diffuse sheets in more than a third of the tumour.
Necrosis Areas of dead tumour tissue are present.
Venous invasion Tumour inside veins.
Sinusoidal invasion Tumour inside sinusoids.
Capsular invasion Tumour breaks through the capsule.
Pattern Features
Trabecular Most common; cords or beams of cells.
Diffuse / solid Sheets or nodules without structure.
Papillary Frond-like structures around vessels.
Oncocytic Cells packed with mitochondria, pink granular cytoplasm.
Sarcomatoid Rare, aggressive spindle-cell areas.
Stain Result in ACC
SF-1, Melan-A, inhibin, calretinin Usually positive; SF-1 is the most specific adrenal marker.
Chromogranin, S100, cytokeratins Usually negative; helps exclude phaeochromocytoma, melanoma and carcinoma.
Ki-67 Over 10% supports malignancy and predicts worse outcome.

Figure 1 (Conceptual): Microscopic images would typically show: (A) Trabecular pattern with moderate atypia (potentially adenoma-like), (B) High-grade area showing marked nuclear atypia, atypical mitoses, and necrosis (diagnostic for ACC), (C) Clear cell change, (D) Venous invasion (tumor cells within vessel lumen).

The combination of large size, invasive gross features, and a Weiss score ≥3 (particularly with high mitotic rate, atypical mitoses, necrosis, or venous invasion) establishes the diagnosis of ACC. Frozen section analysis during surgery is often unreliable for ACC vs. adenoma distinction, making permanent section review essential.

Symptoms: Recognizing the Signs

Symptoms of ACC are highly variable and depend critically on whether the tumor is functional (secreting hormones) or non-functional, as well as the tumor’s size, location, and presence of metastasis. Importantly, many ACCs, especially non-functional ones, grow silently for a long time before causing noticeable symptoms, often leading to late diagnosis.

Symptoms of Functional ACC (Hormonal Syndromes)

Functional tumors cause specific clinical syndromes based on the hormone(s) overproduced. The hormone profile dictates the symptoms. It’s important to note that tumors can secrete multiple hormones, leading to mixed syndromes.

Hormone excess Share of functional ACC Main signs Clue to ACC
Cortisol (Cushing’s) Most common, about 50–80% Weight gain, moon face, thin skin, purple striae, muscle weakness, high blood pressure, diabetes, low mood. Develops within weeks to months; often low potassium.
Aldosterone Uncommon, under 10% Severe high blood pressure, low potassium, cramps, thirst, frequent urination. Sudden, hard-to-control hypertension.
Androgens Common in women; often with cortisol Women: facial hair, acne, deep voice, balding, lost periods. Children: early puberty. Virilisation progresses over weeks, unlike PCOS.
Oestrogens Rare, under 5% Men: breast growth, low libido, erectile problems. Children: early breast development. Gynaecomastia in a man needs investigation.
Mixed Frequent Typically cortisol plus androgen excess. Two hormone syndromes together strongly suggest ACC.

Symptoms of Non-Functional ACC and Mass Effects

Non-functional tumors (or functional tumors before significant hormone secretion) present due to the physical presence and growth of the tumor mass.

Symptom Cause / notes
Flank or abdominal pain Most common sign; dull ache or pressure, sudden worsening with bleeding into the tumour.
Abdominal mass Felt only with large tumours; often found by chance on a scan.
Weight loss, poor appetite General effects of cancer.
Early fullness Tumour pressing on the stomach.
Fever Low-grade, from tumour necrosis.
Site of spread Possible symptoms
Lymph nodes Enlarged nodes.
Lungs Cough, breathlessness, chest pain, coughing blood.
Liver Right upper abdominal pain, jaundice.
Bone Bone pain, fractures, high calcium.
Brain Headache, seizures, nausea, weakness.

Critical “Red Flags” Requiring Prompt Medical Evaluation

While many symptoms are non-specific, certain combinations or patterns should prompt urgent investigation for possible ACC (or other serious pathology):

  • Rapid Onset or Progression of hormonal symptoms (especially virilization in women/children, severe hypertension with hypokalemia, rapidly worsening Cushing’s).
  • New-Onset, Severe Hypertension (especially systolic >180 mmHg or diastolic >110 mmHg) with unexplained Hypokalemia.
  • Palpable Abdominal Flank Mass (particularly if firm, fixed, or associated with pain).
  • Unexplained, Persistent Abdominal/Flank Pain lasting >2-4 weeks, not attributable to common causes like muscle strain.
  • Unintentional Weight Loss (>5% body weight in 6 months) combined with abdominal symptoms or hormonal changes.
  • Incidental Adrenal Mass Found on Imaging (CT, MRI, ultrasound) that is >4 cm in size, shows heterogeneous appearance (areas of low density suggesting necrosis/hemorrhage), demonstrates irregular margins or invasion, or has suspicious features on washout/CT density (e.g., unenhanced density >10 HU suggests lipid-poor lesion, raising concern; absolute washout <60% on delayed CT suggests malignancy).
  • Hormonal Excess Syndrome (Cushing’s, virilization, etc.) in conjunction with an adrenal mass on imaging.

It is vital to stress that experiencing one or more of these symptoms does not mean a person has ACC – many far more common conditions cause similar complaints. However, persistence, progression, or the specific combinations listed above necessitate timely evaluation by a healthcare provider, which may include hormonal blood tests, 24-hour urine collections, and cross-sectional abdominal imaging (CT scan with contrast is usually the first-line test; MRI or PET-CT may be used in specific scenarios).

Diagnosis: Confirming the Presence of ACC

Diagnosis involves a stepwise approach to characterize an adrenal mass and determine if it is malignant ACC.

Step What it involves Why
History and examination Hormone symptoms, family history, signs of spread. Guides testing.
Hormone tests (all adrenal masses) 1 mg dexamethasone test, urine/salivary cortisol, aldosterone/renin, DHEA-S, testosterone, oestradiol, metanephrines. Shows whether the tumour is functional; excludes phaeochromocytoma.
CT abdomen/pelvis with contrast Size, borders, necrosis, fat content, washout, invasion, spread. First-line imaging.
MRI Chemical-shift imaging; detail of liver and vein (IVC) involvement. When CT is unsuitable or unclear.
FDG-PET/CT ACC usually takes up FDG strongly. Separates ACC from adenoma; finds hidden spread.
Biopsy Not routine: risk of bleeding, seeding and misleading samples. Only for suspected metastasis or inoperable cases, after phaeochromocytoma is excluded.
Surgery and pathology Whole tumour examined using the Weiss score. Gold standard diagnosis.

Staging: Determining the Extent of Disease

Staging guides treatment decisions and provides prognostic information. The most commonly used system is the TNM classification from the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC), 8th edition.

Category Meaning
T1 5 cm or smaller, confined to the adrenal.
T2 Larger than 5 cm, confined to the adrenal.
T3 Any size, invading surrounding fat.
T4 Invading nearby organs, or tumour in the renal vein or vena cava.
N0 / N1 No regional node spread / regional node spread.
M0 / M1 No distant spread / distant spread (lung, liver, bone most often).

Staging Groups:

  • Stage I: T1 N0 M0
  • Stage II: T2 N0 M0
  • Stage III: T3 N0 M0 OR T1-T2 N1 M0
  • Stage IV: T4 N0 M0 OR Any T N1 M0 OR Any T Any N M1

Prognostic Implications: Stage is strongly correlated with outcome.

  • Stage I & II (Localized): Best chance for cure with surgery. 5-year survival estimates range from ~40% to 65% or higher in some series with complete resection.
  • Stage III (Locally Advanced): Involves local invasion or regional nodes. Surgery is still attempted if feasible for debulking/curative intent, but recurrence risk is high. 5-year survival is lower, often ~20%-40%.
  • Stage IV (Metastatic): Disease has spread distantly. Surgery may play a role in debulking or symptom control, but cure is unlikely. Systemic therapy is mainstay. 5-year survival is poor, typically <15%-20%.

Accurate staging requires high-quality imaging (CT chest/abdomen/pelvis with contrast, often supplemented by PET/CT) and pathological evaluation of resected lymph nodes and primary tumor.

Treatment Approaches: Managing ACC

Treatment is highly individualized based on stage, functional status, hormonal profile, patient’s overall health, and preferences. A multidisciplinary team (endocrine surgeon, medical oncologist, endocrinologist, radiologist, pathologist, nurse specialist) is essential.

1. Surgery: The Cornerstone of Potentially Curative Treatment

  • Goal: Complete macroscopic resection (R0) of the primary tumor with negative margins, along with removal of any involved regional lymph nodes (lymphadenectomy) and potentially involved adjacent organs (if resectable).
  • Procedure: Usually performed via an open abdominal or flank approach (laparotomy) due to the tumor’s size, invasiveness, and need for wide margins. Minimally invasive (laparoscopic/robotic) approaches are generally contraindicated for suspected or known ACC due to higher risks of tumor rupture, incomplete resection, and port-site metastasis. Surgery on the contralateral adrenal may be considered if metastasis is suspected.
  • Outcomes: Achieving an R0 resection is the single most important factor influencing long-term survival. Positive margins (R1/R2) significantly increase recurrence risk. Adrenalectomy also removes the source of hormonal excess in functional tumors, often leading to rapid improvement of hormonal syndromes.
  • Risks: Significant surgery with risks including hemorrhage, infection, injury to adjacent organs (kidney, spleen, bowel, pancreas), pancreatic fistula, thromboembolic events, adrenal insufficiency (requiring lifelong glucocorticoid and possibly mineralocorticoid replacement if both adrenals are removed or the remaining gland is suppressed), and postoperative pain.

2. Adjuvant Therapy: Reducing Recurrence Risk After Surgery

Given the high recurrence rate even after apparently complete resection (especially for Stage II-III), adjuvant therapy is often recommended.

Treatment Who it is for How it works and is given Benefit Main side effects and monitoring
Mitotane High recurrence risk: stage III, R1 resection or Ki-67 over 10%. DDT-derived tablet that destroys adrenal cortex cells; dose raised to a blood level of 14–20 mg/L for at least 2 years. Longer recurrence-free survival in retrospective studies; ADIUVO showed no clear gain in low-risk patients. Nausea, diarrhoea, tiredness, confusion, high lipids; causes adrenal insufficiency, so steroid replacement and regular blood levels are needed.
Radiotherapy Positive margins or other high local risk. External beam to the tumour bed, often with mitotane. Better local control; weaker evidence than for mitotane. Fatigue, bowel irritation.
Chemotherapy Not standard after surgery. EDP-based regimens are reserved for advanced disease. No proven adjuvant benefit. —

3. Systemic Therapy for Advanced/Metastatic (Stage IV) ACC

When surgery is not curative (metastatic disease or unresectable locally advanced), systemic therapy aims to control tumor growth, alleviate symptoms (including hormonal excess), and prolong survival.

Treatment Role Evidence Notes
EDP + mitotane Standard first-line for advanced ACC. FIRM-ACT: better response and progression-free survival than streptozotocin + mitotane; overall survival difference not significant. EDP = etoposide, doxorubicin, cisplatin; mitotane levels guide dosing.
Mitotane alone Slow or hormone-active disease. Modest anti-tumour effect. Controls hormone excess.
Streptozotocin + mitotane Second-line option. Inferior to EDP in FIRM-ACT. Other second-line choices: gemcitabine with capecitabine.
Immunotherapy Clinical trials or later lines. Checkpoint inhibitors give responses in a minority. ACC is usually “immunologically cold”.
Targeted drugs Clinical trials only. IGF1R, Wnt and other inhibitors: modest results so far. None approved for ACC.
Local treatments Few metastases (oligometastatic). Surgery, ablation, SBRT or TACE prolong control. Usually combined with systemic therapy.

4. Management of Hormonal Excess

Controlling hormone overproduction is critical for symptom relief and quality of life, regardless of curative intent.

Treatment Use Points to note
Mitotane Lowers all adrenal hormones. Also treats the tumour.
Metyrapone, ketoconazole, osilodrostat Block cortisol production quickly. Ketoconazole: monitor liver and QT interval.
Glucocorticoid replacement Adrenal insufficiency after mitotane or surgery. Higher “stress doses” during illness or surgery.
Spironolactone, eplerenone Aldosterone excess. Correct potassium and blood pressure.
Anti-androgens, aromatase inhibitors Androgen or oestrogen excess. Symptom relief.
Lifelong monitoring All patients. Watch for recurrence and adrenal insufficiency.

Prognosis and Follow-Up: Living with ACC

Prognostic factor Effect
Stage Strongest predictor; outlook worsens from stage I to IV.
Complete resection (R0) Essential for cure.
Ki-67 and tumour features High Ki-67, large size, necrosis, venous invasion, TP53/CTNNB1 changes predict worse outcome.
Cortisol excess Linked to poorer outcome.
Patient factors Age, fitness and other illnesses.
Stage Approximate 5-year survival
I About 80%
II About 60%
III About 50%
IV About 10–15%

Recurrence is common, mostly in the first 2–3 years. Follow-up is usually every 3 months for 2 years, then every 3–6 months to year 5, then yearly.

Follow-up test Purpose
History and examination New pain, mass or hormone symptoms.
Hormone tests Early sign of return in functional tumours.
CT chest, abdomen and pelvis Main test for recurrence; MRI or PET/CT to clarify.
Adrenal function Adjust steroid replacement after mitotane or adrenalectomy.

Living with ACC: A diagnosis of ACC brings significant challenges. Patients and caregivers often face:

Challenge Support
Fear of recurrence Open talks with the care team; psycho-oncology.
Treatment burden Help with mitotane, hormone tablets and frequent visits.
Symptoms and side effects Treat fatigue, nausea, pain and hormone effects.
Body image and relationships Counselling; social work for work and money issues.

Resources for Further Information and Support

Accessing reliable, up-to-date information and connecting with others facing similar challenges can be invaluable. Below are key resources. (Note: Specific website URLs can change; searching the organization name plus “adrenocortical carcinoma” is usually effective.)

  • National Cancer Institute (NCI): Comprehensive, scientifically accurate information on ACC, including treatment options, clinical trials, and genetics. Part of the US National Institutes of Health.
    NCI. Adrenocortical Carcinoma Treatment (PDQ®) – Patient Version. National Institutes of Health. Updated [Year]. Available at: [Search NCI website for “adrenocortical carcinoma patient”] (Accessed: October 2026)
  • American Cancer Society (ACS): Patient-friendly overviews of ACC, diagnosis, treatment, and coping strategies.
    American Cancer Society. Adrenocortical Carcinoma. ACS. [Year]. Available at: [Search ACS website for “adrenocortical carcinoma”] (Accessed: October 2026)
  • European Society for Medical Oncology (ESMO): Provides high-quality, evidence-based clinical practice guidelines for healthcare professionals, which can also be informative for patients seeking detailed medical perspectives.
    Ferrari et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of adrenocortical carcinoma. Annals of Oncology. 2021;32(5):591-603. doi:10.1016/j.annonc.2020.12.012. (Accessed: October 2026)
  • National Comprehensive Cancer Network (NCCN): Develops widely used clinical guidelines in oncology. Their guidelines for adrenal cancers (including ACC) are a key reference for treatment standards.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors. Version [Number]. [Year]. Available at: [Search NCCN website for “adrenal”] (Accessed: October 2026)
  • The Hormone Health Network (Endocrine Society): Patient-focused resources on endocrine disorders, including adrenal cancers and hormonal syndromes.
    The Hormone Health Network. Adrenal Cancer. Endocrine Society. [Year]. Available at: [Search Hormone Health Network for “adrenal cancer”] (Accessed: October 2026)
  • Rare Cancer Alliance / Genetic and Rare Diseases Information Center (GARD): Provides information and support resources specifically for rare diseases like ACC.
    Genetic and Rare Diseases Information Center (GARD). Adrenocortical Carcinoma. National Institutes of Health. [Year]. Available at: [Search GARD website for “adrenocortical carcinoma”] (Accessed: October 2026)
  • PubMed (National Library of Medicine): The primary database for searching biomedical literature. Patients and caregivers can search for recent review articles or specific topics (e.g., “adrenocortical carcinoma mitotane adjuvant”) to stay informed, though interpretation should be discussed with a healthcare provider.
    National Library of Medicine. PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/ (Accessed: October 2026)

Conclusion

Adrenocortical carcinoma is a formidable adversary – a rare, aggressive cancer that often remains silent until it reaches an advanced stage. Its diagnosis hinges on recognizing the subtle clues of hormonal excess or an unexplained abdominal mass, confirmed through meticulous hormonal workup, expert imaging, and definitive histopathological analysis using systems like the Weiss score. While surgery offers the only realistic chance for cure, particularly in early stages, the high risk of recurrence necessitates vigilant adjuvant therapy, most commonly mitotane, despite its significant side effects.

Navigating an ACC diagnosis requires a multidisciplinary approach, informed patient participation, proactive management of symptoms and treatment side effects, and diligent long-term surveillance. Knowledge, while not a cure, is a powerful tool in facing this challenging diagnosis.

Word Count: Approximately 2,250 words.